Comparative Pharmacology
Head-to-head clinical analysis: MINTEZOL versus NICLOCIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINTEZOL versus NICLOCIDE.
MINTEZOL vs NICLOCIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiabendazole inhibits the mitochondrial fumarate reductase system in susceptible helminths, disrupting energy metabolism.
Inhibits oxidative phosphorylation in cestodes, leading to paralysis and death of the parasite.
50 mg/kg/day orally in 2-3 divided doses, maximum 3 g/day, for 2-3 days.
2 g orally as a single dose, chewed thoroughly, for taeniasis; may repeat in 1 week for hymenolepiasis.
None Documented
None Documented
Terminal elimination half-life: 2-8 hours (mean 4 hours). Hepatic impairment prolongs; dose adjustment recommended.
The terminal elimination half-life of niclosamide is approximately 2-6 hours in patients with normal renal function; however, clinical efficacy against cestodes is prolonged due to its local action in the gastrointestinal tract.
Renal: 90% within 24 hours (5% unchanged, 85% as metabolites). Fecal: <10%.
Niclosamide is predominantly excreted in feces as unchanged drug and metabolites after oral administration. Renal excretion of metabolites accounts for less than 2% of an administered dose. Approximately 70% of the dose is recovered in feces within 2-3 days.
Category C
Category C
Anthelmintic
Anthelmintic